About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Nashville | 367 Studies

Clinical Trials LymphomaNashville

Lymphoma Clinical Trials in Nashville

Find 367 clinical trials for lymphoma near Nashville, Tennessee. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Nashville

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 161-180 of 367 trials

UnknownPhase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALLIn the proposed study, escalating doses of inotuzumab ozogamicin will be added to a standard pediatric inspired re-induction regimen and administered to patients with relapsed or…NCT03962465·Nashville, Tennessee and 3 others CompletedLenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin LymphomaRATIONALE: Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer.NCT00765245·Chapel Hill, North Carolina and 3 others CompletedA Study of INCB050465 in Relapsed or Refractory Follicular LymphomaThe purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma.NCT03126019·Phoenix, Arizona and 82 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedStudy of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)The purpose of this study is to determine whether Nivolumab is effective in the treatment of DLBCL in patients that have failed or are ineligible for ASCTNCT02038933·Phoenix, Arizona and 45 others

CompletedSafety of PCI-32765 in Chronic Lymphocytic LeukemiaThe purpose of this study is to establish the safety and efficacy of orally administered PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.NCT01105247·Stanford, California and 9 others

CompletedTemsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin LymphomaThis phase I trial studies the side effects and the best dose of temsirolimus when given together with dexamethasone, mitoxantrone hydrochloride, vincristine sulfate, and…NCT01403415·Birmingham, Alabama and 30 others

TerminatedLong-Term Follow-Up Study of Subjects Treated With ACTR T Cell ProductSubjects treated with an ACTR product may participate in this long-term follow-up study after the completion of the final scheduled visit in the parent clinical study or other…NCT02840110·Gilbert, Arizona and 15 others

Active not recruitingTafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsThis is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody…NCT04824092·Daphne, Alabama and 306 others

RecruitingStudy of VIP943 in Subjects With Advanced CD123+ Hematologic MalignanciesDose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects…NCT06034275·Birmingham, Alabama and 4 others

CompletedA Study of LY3023414 in Participants With Advanced CancerThe purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer.NCT01655225·Los Angeles, California and 7 others

RecruitingEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use DisorderThe primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in…NCT06651177·Jacksonville, Florida and 8 others

TerminatedPresence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell TransplantRATIONALE: Studying samples of semen from cancer survivors in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.NCT01077440·Nashville, Tennessee

CompletedPROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCLThe purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in…NCT03543813·Birmingham, Alabama and 24 others

TerminatedA Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsMulticenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.NCT02663518·Duarte, California and 50 others

RecruitingA Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory…NCT06393738·New Haven, Connecticut and 20 others

Active not recruitingA Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaThe purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R)…NCT05100862·Fresno, California and 263 others

RecruitingInotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyThis phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute…NCT03959085·Birmingham, Alabama and 230 others

CompletedBendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular LymphomaRATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping…NCT01216683·Greenbrae, California and 226 others

CompletedCombination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00002941·Birmingham, Alabama and 234 others

CompletedDexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell LymphomaRATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells.NCT00006345·Miami, Florida and 10 others

PreviousPage 9 of 19Next

Other Conditions in Nashville

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia